To
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

Script Name: Earkart Limited
Scrip Code: 544549
ISIN: INE1A8F01035

Subject: Earning Presentation

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find enclosed the Earning Presentation on the unaudited (standalone and consolidated) Financial results for the half year ended September 30, 2026.

The same will be made available on the Company's website https://www.earkart.in

This is for your information, records and appropriate dissemination.

Yours faithfully,
For Earkart Limited

Preeti Srivastava
Digitally signed by Preeti Srivastava
Date: 2026.11.21 19:45:27 +05'30'

Preeti Srivastava
Company Secretary & Compliance Officer
Membership No: A31615

Date: 21 November 2026
Place: Noida

Encl: As above

earKART
REDEFINING HEARING CARE

BSE SME: **544549**

EARKART LIMITED

Redefining Hearing Care



Investor Presentation
H1 FY27

earKART
REDEFINING HEARING CARE

The Hearing Care Gap Is Widening



01

HEARING LOSS IS GROWING

430 MILLION
people need rehabilitation today

2.5 BILLION
will have some hearing loss by 2050



02

CARE IS NOT REACHING PEOPLE

OVER 400 MILLION
could benefit from a hearing device

FEWER THAN 20%
of that need is met



03

INDIA'S GAP IS WIDEST

1 audiologist per **2 lakh people**

and the shortage persists



Sources : Third-Party Market Research

Hearing loss is a growing global burden

A large, growing, and under-served health burden, with a high-return case for action

430M
people need rehabilitation for disabling hearing loss today

2.5B
projected to have some degree of hearing loss by 2050

US $1T
annual global cost of unaddressed hearing loss

16X
return per US$1 invested in ear and hearing care over 10 years



Supporting Metrics

700M+	will need rehabilitation by 2050 (1 in 10 people)
80%	of those affected live in low- and middle-income countries
>25%	of people over 60 have disabling hearing loss
95.1M	children aged 5-19 live with hearing loss
1B+	young adults at risk from unsafe listening practices

Source: Third-Party MarketResearch

Every one of these people must be tested before they can be treated.
Diagnosis is the bottleneck.

Hearing care is not reaching the people who need it

The constraint is not the hearing aid. It is the expert who tests and fits it.

Over
400 million
people could benefit from a hearing device

Fewer than
20%
of that need is met.

WHO's 2024 guidance says the old model of one patient travelling to one audiologist cannot scale. Its answer is task sharing between specialists and trained non-specialists.

WHO has named the problem and the solution. That solution is the design principle behind OMNI.



Source: Third-Party Market Research

India's gap is widest where need is largest

India has a large hearing-care need, but a structural shortage of audiologists' limits access

1: 2L
audiologist per 2 lakh people

6%–26.9%
estimated population affected by hearing loss

2,500
BASLP graduates entering the workforce annually

US$55B
estimated annual economic cost of hearing loss in India

1 : 85K
ENT specialist per ~85K people, versus ~1 audiologist per 2 lakh

37.5%
prevalence among people aged 40–59

2026 SURVEY
workforce shortage remains a key barrier to hearing screening

66.6%
prevalence among people above 70



The economics favour treatment. Access is what is missing

Source: Third-Party Market Research

Two Ways to Solve India's Hearing-Care Gap

Two Solutions to One Problem: Too Few Audiologists, Too Far Away

Path A

Train More Audiologists

Necessary, but it takes time



Raise the audiologist-to-population ratio by expanding BASLP seats and training institutions



A new audiologist takes 4 to 5 years to qualify, and enrolling and building capacity at scale takes longer still

This must be done, but it is a long-term fix. It cannot solve today's access gap.

Path B

Reach More People with Every Audiologist

The problem is access, not just numbers.



Audiologists are concentrated in metro cities, while patients live in small towns and remote areas



Bringing patients to audiologists is the real barrier: distance, travel cost and lost time keep people from care



Each audiologist can remotely serve 4–7 clinics, extending specialist expertise across multiple locations.



No wait for new talent to qualify

This extends reach right now, using the audiologists we already have.

Training builds the future. Extending reach serves the present.

We need both, but only extending each audiologist's reach can close the access gap today.

How the three themes map to Earkart Limited

01

GROWING BURDEN



Earkart's response

Own hearing-aid brands (EQFY, Fame, Radius, Tiny) made in Noida; exports to Sri Lanka, Bangladesh and Nepal; subsidiaries in the US and UK



02

CARE NOT REACHING PEOPLE



Earkart's response

OMNI 2.0: one audiologist tests and fits across many clinics remotely



03

INDIA'S ACCESS GAP



Earkart's response

Shop-in-Shop clinics (105 live, 55+ cities) plus GeM and ALIMCO supply for government programmes



Why We Exist:
Hearing Care for Every Indian Town

Affordable | Accessible | Scalable

Tens of millions of Indians live with hearing loss, and access to qualified audiologists remains limited, particularly beyond major cities. We believe a hearing test, expert diagnosis and a properly fitted hearing aid should be available in every district town, at a price family can afford.

Our approach is to make hearing care more affordable, bring audiology expertise closer to patients and make access scalable.



ACCESSIBLE

OMNI brings the audiologist to the patient. This is Path B in action. Through tele-audiology, a trained clinic assistant supports the patient locally while a qualified audiologist consults remotely. Each audiologist can remotely serve 4–7 clinics, extending specialist expertise across multiple locations., so families in district towns no longer need to travel to a metro for expert care.



AFFORDABLE

In-house hearing-aid manufacturing keeps quality devices within reach of families.



SCALABLE

Our growing clinic network brings these services closer to communities across India.

We don't wait for more audiologists to reach more Indians. We extend the reach of the ones we have.

Earkart at a Glance

India's integrated hearing healthcare platform, from diagnostics to devices to technology and ENT care.

Earkart Limited is providing integrated hearing healthcare across India, spanning diagnostics, hearing aids, technology-enabled solutions and ENT pharmaceuticals.

What we do



Hearing aids

EQFY, Fame, Radius and Tiny brands with accessories, made in-house



Diagnostics and technology

patented OMNI audiometer, backed by 20+ audiology experts



ENT pharmaceuticals

Formulations for nasal allergy, tinnitus and earwax, sold through SIS clinics



Reach

SIS network in Tier 2 and Tier 3 cities, plus government supply through GeM and ALIMCO

Company snapshot

- Patents: 01
- ISO 13485, CDSCO and BIS compliant
- Forbes DGEMS 2025 Select 200: top 200 high-impact companies with global business potential
- Founded 2021 | 105 SIS outlets | 24 states covered
- 7 ENT Pharmaceutical Formulations

Financial metrics [H1FY27]

₹3107.00 lakhs
Revenue from operations

₹183.35 lakhs
EBITDA

5.90%
EBITDA margin

₹71.77 lakhs
PAT

2.30%
PAT margin

1.11%
ROE

1.90%
ROCE

Revenue mix
59.05% - Government
40.95% - Private

Our Journey

2021

- Company incorporated; Rohit Misra takes over as promoter
- Launch of earKART CRM and dealer app



2022

- BIS licence received
- First government order for 10,000 hearing-aid units
- Patent application filed for OMNI



2023

- ISO 13485:2016 certification
- Licence to manufacture and distribute Class A and B medical devices



2024

- Launch of ENT Shop-in-Shop (SIS) model and the OMNI remote audiometry device
- Conversion into a public limited company



2025

- Listed on BSE SME (scrip code 544549)
- Indian patent granted for OMNI (October 2025)



2026

- Earkart Inc. (USA) incorporated as a wholly-owned subsidiary
- Earkart Health Limited (UK) incorporated with a 65% stake
- Wholly-owned subsidiaries incorporated for pharmaceuticals and healthcare services
- Multiple ALIMCO orders secured
- Successfully received U.S. FDA registration for its hearing aid product portfolio



Product Portfolio

Four hearing-aid brands, a patented diagnostic platform and a new ENT pharma range, built for affordable care.

Digital hearing aids

Programmable | Rechargeable | Bluetooth-enabled | Affordable



EQFY

Receiver-in-Canal (RIC)

Digital aid built for modern hearing-care needs



Fame

Behind-the-Ear (BTE)

Trimmer-adjustable; models P, SP and 2T



Radius

Behind-the-Ear (BTE)

Programmable; moderate to profound loss; 200-5,000 Hz; up to 15 days battery life



Tiny

Completely-in-Canal (CIC)

Rechargeable, 16-channel; 500-6,000 Hz; up to 70 hours per charge

Diagnostics

Earkart OMNI: patented audiology platform for audiometry, tympanometry, OAE and video otoscopy, with remote audiology support.



ENT pharmaceutical formulations

- 7 products: nasal sprays, tablets, capsules and Ear drops
- Cover nasal allergy, tinnitus and earwax management



Accessories

- Noise-protection ear buds, cleaning brush, wax guard, battery tester, batteries, third-party hearing aids and parts.



Beyond hearing aids

- Rehabilitation and education: MSIED and TLM kits
- Mobility: foldable walkers



How Earkart Works

01

Shop-in-Shop (SIS) model

- Offers own brands (EQFY, Fame, Radius, Tiny), ENT Pharmaceutical formulations, third-party accessories and rehabilitation products
- 105 SIS clinics across ENT, with OMNI installed so a remote audiologist can test and fit patients through a trained clinic assistant
- Expanding across Tier 2 and Tier 3 cities, aiming to build the largest hearing-care clinic network by 2027



02

Private business

- Extensive network of retailers, wholesalers and direct customer engagement
- The diversified distribution network widens market reach and strengthens customer relationships across regions



03

Service revenue

- Revenue from audiometry diagnostic tests, conversion charges and consultancy services
- The service portfolio supports recurring income and deepens customer engagement



04

Government business (B2G)

- Strong presence on the Government e-Marketplace (GeM) portal
- Long-standing association with ALIMCO as a supplier
- Participates in government-led hearing healthcare programmes, supporting consistent institutional demand



OMNI 2.0:
Remote audiology for towns without an audiologist

What it is

- A compact,propriertary technology drive system that lets an audiologist at Earkart's command centre, test hearing and fit hearing aids for patients remotely over live video, 11- inch screen easy to carry, value proposition- Enables a single audiologist to serve 4–7 clinics through remote consultations.
- Indian patent granted in 2025 (filed 2022): "Smart Sound Treatment and Diagnosis System and Method Thereof"

Capabilities

Tests:
Video otoscopy, Air and Bone conduction audiometry, Tympanometry and OAE (including newborn screening)

Fitting:
Programs Bluetooth-enabled and any programmable hearing aid, of any brand, in real time

Portable:
11-inch propriertary technology drive systemt with wireless connectivity and a Li-ion battery (8 hours per charge)



Value proposition | A single audiologist can manage hearing assessments and hearing-aid programming across 4–7 clinics remotely, improving specialist availability and clinic reach.

Traction and Economics:
SIS clinics scale on OMNI and ENT pharmaceutical formulations

Every SIS clinic runs on existing ENT footfall. OMNI and new formulations add revenue per patient with no acquisition spend.



55+
cities



300+
clinic applications from ENT conference



20+
audiologists supporting the network



7
ENT pharmaceutical formulations launched

Why OMNI works inside SIS clinics

01

Zero customer acquisition cost. Patients already walk into ENT clinics, so OMNI converts existing footfall instead of buying leads.

02

Staff-run, lightly supported. We train the clinic's own team, and one remote audiologist covers up to five clinics. Setup is about ₹3 lakh per clinic.

03

Stronger with every clinic. Each new clinic adds its own patient flow while sharing the same audiologist network.

ENT pharmaceutical formulations on the same channel

01

Currently, all 7 products are sold through SIS clinics, eliminating the need for a separate distribution network.

02

Plans to expand into independent sales once recurring revenue is established.

Leadership Driving the Vision



Mr. Rohit Misra

Promoter and Managing Director

Experience: 30+ years

Qualification: B.Sc. (Meerut University) and Diploma in Marketing Management

Responsibility: leads overall company strategy, business development and innovation; sets the Company's vision and growth agenda

Key achievement: led the team to a Guinness World Record for fitting hearing aids to the most hearing-impaired individuals in a single day



Ms. Monika Misra

Promoter and Whole-Time Director

Experience: 25+ years

Qualification: B.Sc. (1993) and M.Sc. (1995), Meerut University; B.Ed. (1996),

Responsibility: oversees daily operations and the audiology and customer-service teams



Mr. Ajay Kumar Giri

Director and CFO

Experience: 17+ years

Qualification: M.Com. (2014, Sikkim Manipal University)

Responsibility: leads the accounts and finance division



Mr. Rahul Salesha

Director

Experience: 19+ years

Qualification: B.Com. (2008, Mumbai University) and M.Sc. (2009, Aston University)

Responsibility: oversees product development, strategic planning and business growth

Manufacturing Facility

Facility

Noida, Uttar Pradesh

13,000 sq ft

(expanded from 4,500 sq ft at IPO)

Installed capacity of about

2,00,000 units a year

with headroom for a second shift

CDSCO-approved


manufacturing to

ISO 13485:2016 standards










Capabilities

- End-to-end hearing-aid production: MIC processing, receiver integration and BTE assembly
- In-house PCBA integration and testing
- Quality-assurance lab, with equipment upgrades under way to expand testing capacity




Product focus

- Digitally programmable RIC and BTE hearing aids under the EQFY, Radius and Fame brands
- In-house R&D driving the shift from analogue to fully digital, programmable lines



Geographical Presence

Earkart has a presence across 24 states and 3 Union Territories.



Corporate Structure and Shareholding

Subsidiaries

Entity	Country	Holding	Focus
Earkart Inc.	US	**100%**	Hearing-care distribution and services in the US
Earkart Health Limited	UK	**65%**	Hearing-care distribution and services in the UK
Earkart Pharmaceuticals Pvt. Ltd.	India	**100%**	Pharma business

Shareholding pattern

(as at 30th September 2026)



U.S. FDA Registration

A Strategic Milestone in Global Expansion

Strengthening Regulatory Foundations. Unlocking International Growth Opportunities.



U.S. FDA Registration

Successfully completed establishment registration with active medical device listings across four hearing aid categories.



Diversified Product Portfolio

Prescription, OTC, Wireless Prescription and Wireless OTC hearing aids.



Growing Market Opportunity

U.S. hearing aids market projected to grow from **USD 4.65 Bn** (2026) to **USD 9.57 Bn** by 2035, at **8.4%** CAGR.



Multiple Growth Avenues

Exploring U.S. distribution partnerships across retail, online and audiology networks.



Make in India

Global Reach: Leveraging indigenous product development and manufacturing capabilities to explore international markets.

Industry Overview:
The global hearing-aid market

The global hearing-aids market, valued at US$ 9.1 billion in 2025, is projected to grow at a 7.0% CAGR to US$ 17.9 billion by 2035.

Global hearing-aid industry
(US$ billion)



Key growth drivers

Ageing population
The 60+ group reaches 1.4 billion by 2030

Technology
AI sound processing, rechargeable and Bluetooth devices

Policy support
Awareness campaigns and reimbursement

Source: Hearing Aids Market (2026 - 2035)

Profit and Loss statement, Consolidated


(₹ lakh, except EPS)

Particulars	H1 FY27	H1 FY26	YoY %	H2 FY26	HoH %	FY26
Revenue from operations	3107.00	2,228.57	39.42%	3,174.96	(2.14%)	5,403.53
Other income	18.07	2.44	640.57%	8.20	120.37%	10.65
Total income	3125.07	2,231.01	40.07%	3,183.16	(1.82%)	5,414.18
Total expenditure	2941.72	1,915.23	53.60%	2,653.15	10.88%	4,568.38
EBITDA	183.35	315.78	(41.94%)	530.01	(65.41%)	845.79
EBITDA margin	5.90%	14.00%	(810 bps)	17.00%	(1110 bps)	16.00%
Depreciation	59.32	22.62	162.25%	43.41	36.65%	66.03
Interest	7.39	38.61	(80.86%)	15.60	(52.63%)	54.21
Profit before tax	116.63	254.56	(54.18%)	470.99	(75.24%)	725.56
Tax	44.86	69.23	(35.20%)	163.10	(72.50%)	232.33
PAT	71.77	185.33	(61.27%)	307.90	(76.69%)	493.23
PAT margin	2.30%	8.00%	(570 bps)	10.00%	(770 bps)	9.13%
EPS (₹)	0.52	1.35	(61.48%)	2.49	(79.12%)	3.99

Revenue Bifurcation


(H1 FY27 |Unaudited | ₹ lakh)

By Segment (Half yearly)



Total = ₹3,107.00

By Geography



Total = ₹3,107.00

Balance Sheet

(₹ lakh)

Particulars	As at 30 September 2026	As at 31 March 2026	As at 31 March 2025
Share capital	1,375.39	1,375.39	1,043.89
Reserves	5119	5,059.13	936.71
Short-term borrowings	122.32	0.24	495.93
Trade payables	279.21	180.09	301.67
Other liabilities	203.77	334.35	246.23
Total liabilities	**7,099.69**	**6,949.20**	**3,024.43**
Fixed assets	947.26	587.75	108.83
Other non-current assets	641.63	194.25	216.04
Trade receivables	2,596.47	2,106.90	1,856.81
Other current assets	2,914.33	4,060.30	842.75
Total assets	**7,099.69**	**6,949.20**	**3,024.43**

Growth Prospects

The hearing-care gap is global and growing. Earkart is positioned to scale across India, across borders and across ENT care to address it.



Pan-India SIS network: taking the audiologist to the patient

- Expanding OMNI-enabled SIS clinics across India to close the access gap
- OMNI extends expert testing and fitting to towns that have never had an audiologist
- Rising demand for OMNI beyond India opens the way to take the same model global



Global expansion: the same burden, a wider market

- Growing international demand for OMNI creates a runway beyond India
- Subsidiaries in the US (Earkart Inc., wholly owned) and the UK (Earkart Health Limited, 65% owned) to pursue it
- Exports to Sri Lanka, Bangladesh and Nepal provide a base to build on



Integrated ENT care: a wider platform on the same clinics

- Pharma subsidiary set up and ENT pharmaceuticalformulations launched through SIS clinics
- New ENT offerings set to make each clinic a fuller ENT care destination

Conclusion

Through OMNI, EarKart aims to bridge the hearing-care access gap by bringing audiology expertise closer to patients. Supported by an expanding SIS clinic network, technology-led hearing solutions and a growing ENT portfolio, the company is extending its reach across India and global markets to make quality hearing care accessible to more people.

Event Participation

EarKart Limited at ISOCON 2026

EarKart Limited participated in **ISOCON 2026**, held in Amritsar on **9-10 October 2026**, showcasing its hearing healthcare solutions, proprietary OMNI technology, remote audiology capabilities and ENT pharmaceutical portfolio.

The engagement was led by **Mr. Rahul Salesha (Director)** and **Ms. Monika Misra (Promoter & Whole-Time Director)**, focusing on interactions with ENT specialists and healthcare professionals, demonstrating technology capabilities and exploring potential business collaborations.











Disclaimer

This presentation and the accompanying slides (the "Presentation"), which have been prepared by EarKart Limited (the "Company'), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks.

The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



THANK YOU

earKART
REDEFINING HEARING CARE

Preeti Srivastava

Company Secretary

ir@earkart.in

FINPORTAL

Abhishek Bhutra | Himanshu Jain

+91 80006 85556 |+91 99987 81853

ir@finportalin.com

Request Meeting & Investor Kit